Update shared on 25 Nov 2025
Fair value Increased 0.53%Analysts have raised their price target for Daiichi Sankyo Company from ¥5,517.06 to ¥5,546.47, citing slightly higher revenue growth expectations. This increase offsets a modest rise in the discount rate and a marginal dip in projected profit margins.
What's in the News
- Daiichi Sankyo and AstraZeneca’s DATROWAY (datopotamab deruxtecan) demonstrated significant improvements in overall survival and progression-free survival as a first-line treatment for metastatic triple-negative breast cancer patients in the TROPION-Breast02 phase 3 trial.
- ENHERTU (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab, and pertuzumab showed an 11.2% improvement in complete response rates compared to standard chemotherapy in high-risk, early-stage HER2-positive breast cancer in the DESTINY-Breast11 trial.
- Raludotatug deruxtecan (R-DXd) was granted Breakthrough Therapy Designation by the U.S. FDA for use in platinum-resistant ovarian and related cancers, based on promising results from ongoing clinical trials.
- Daiichi Sankyo announced a strategic research collaboration with General Proximity to leverage the OmniTAC platform for oncology drug discovery targeting traditionally undruggable proteins.
- The company expanded its global research presence by establishing the Daiichi Sankyo Research Institute in San Diego, its third international R&D hub after Boston and Munich.
Valuation Changes
- Consensus Analyst Price Target has risen slightly, moving from ¥5,517.06 to ¥5,546.47.
- The Discount Rate increased marginally from 4.72% to 4.8%.
- Revenue Growth expectation improved from 11.05% to 11.31%.
- Net Profit Margin forecast dipped modestly, shifting from 17.05% to 16.82%.
- The future P/E ratio estimate edged higher, increasing from 24.26x to 24.54x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.